Preferred Imaging for Target Volume Delineation for Radiotherapy of Recurrent Glioblastoma: A Literature Review of the Available Evidence.
Francesco CucciaFatemeh JafariSalvatore D'AlessandroGiuseppe CarrubaGiuseppe CraparoGiovanni TringaliLivio BlasiGiuseppe FerreraPublished in: Journal of personalized medicine (2024)
In the setting of recurrent glioblastoma, contrast-enhanced T1-weighted sequences were preferred for target delineation, allowing clinicians to deliver a safe and effective therapeutic option; amino acid PET imaging may represent a useful device to discriminate radionecrosis from recurrent disease. Future investigations, including the ongoing GLIAA, NOA-10, ARO 2013/1 trial, will aim to refine approaches and standardize methodologies for improved outcomes in recurrent glioblastoma re-irradiation.
Keyphrases
- contrast enhanced
- pet imaging
- magnetic resonance
- magnetic resonance imaging
- computed tomography
- diffusion weighted
- amino acid
- high resolution
- early stage
- clinical trial
- palliative care
- radiation therapy
- study protocol
- adipose tissue
- locally advanced
- metabolic syndrome
- squamous cell carcinoma
- mass spectrometry
- phase ii
- weight loss
- insulin resistance
- pet ct
- genetic diversity